Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Director Dealing and Share Option Grant

30 Apr 2012 07:00

RNS Number : 3157C
PuriCore Plc
30 April 2012
 



PuriCore plc

 

Director Dealing and Share Option Grant

 

PuriCore (LSE: PURI), the water-based clean technology company, announces today a director dealing and share option grant, in accordance with the Disclosure and Transparency Rules.

Director Dealing

The Company announces that on 27 April 2012 the following Director purchased shares in the Company, as set out below.

Name

 

Number of shares purchased

Purchase price of shares

Shareholding following the acquisition

% of issued share capital

Michael R.D. Ashton

Non-Executive Chairman

9,650

9,700

63p

64p

 

19,350

 

0.08%

 

 

Senior Independent Non-Executive Director Share Option Grant

PuriCore also announces it has issued share options to the Company's Senior Independent Non-Executive Director as set forth below. The share options have an exercise price of 64.58p, which is 5% over the closing market price of the Company's ordinary shares on 27 April 2012, and a five-year term.

Name

Number of share options granted

Vesting

James Walsh, PhD

Senior Independent Non-Executive Director

35,000

½ on 27 April 2013;

½ on 27 April 2014

 

Enquiries:

FTI Consulting

Susan Quigley

Victoria Foster Mitchell

+44 (0) 20 7831 3113

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including supermarketretail, medical device disinfection, and wound care. PuriCore's Solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUROVRUBASORR

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS